



## Drug Prior Authorization Form Verzenio (abemaciclib)

The purpose of this form is to obtain information required to assess your drug claim.

**IMPORTANT:** Please answer all questions. Your claim assessment will be delayed if this form is incomplete or contains errors.

**Any costs incurred for the completion of this form are the responsibility of the plan member/patient.**

Canada Life recognizes and respects the importance of privacy. Personal information collected is used for the purposes of assessing eligibility for this drug and for administering the group benefits plan. For a copy of our Privacy Guidelines, or if you have questions about Canada Life’s personal information policies and practices (including with respect to service providers), refer to [www.canadalife.com](http://www.canadalife.com) or write to Canada Life’s Chief Compliance Officer.

I authorize Canada Life, any healthcare provider, my plan administrator, any insurance or reinsurance company, administrators of government benefits or patient assistance programs or other benefits programs, other organizations, or service providers working with Canada Life or any of the above, located inside or outside Canada, to exchange personal information when relevant and necessary for these purposes. I understand that personal information may be subject to disclosure to those authorized under applicable law within or outside Canada.

I acknowledge that the personal information is needed to assess eligibility for this drug and to administer the group benefits plan. I acknowledge that providing consent will help Canada Life to assess my claim and that refusing to consent may result in delay or denial of my claim. Canada Life reserves the right to audit the information provided on this form at any time and this consent extends to any audit of my claim. This consent may be revoked by me at any time by sending written instruction to that effect.

I also consent to the use of my personal information for Canada Life and its affiliates’ internal data management and analytics purposes.

If the patient is a person other than myself, I confirm that the patient has given their consent to provide their personal information and for Canada Life to use and disclose it as set out above.

I certify that the information given below is true, correct, and complete to the best of my knowledge. Failure to provide true, correct and complete information on this form could result in revocation of any approval decision, a requirement to repay paid claims or other appropriate action.

Plan Member’s signature: \_\_\_\_\_

Date: \_\_\_\_\_

### Form Completion Instructions:

1. Complete “Patient Information” sections.
2. Have the prescribing physician complete the “Physician Information” sections.
3. Send all pages of the completed form to us by mail, fax or email as noted below.

**Note:** As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

**Mail to:** The Canada Life Assurance Company  
Drug Claims Management  
PO Box 6000  
Winnipeg MB R3C 3A5

**Fax to:** The Canada Life Assurance Company  
Fax 1-204-946-7664  
Attention: Drug Claims Management

**Email to:** [cldrug.services@canadalife.com](mailto:cldrug.services@canadalife.com)  
Attention: Drug Claims Management

For additional information regarding Prior Authorization and Health Case Management, please visit our Canada Life website at [www.canadalife.com](http://www.canadalife.com) or contact Group Customer Contact Services at 1-800-957-9777.

(Continued on next page)

## Patient Information Verzenio (abemaciclib)

**Plan Member Information – Complete all sections of this page (please print)**

Plan Member:		Patient Name:	
Plan Name:	Plan Number:	Plan Member ID Number:	
Patient Date of Birth (DD/MM/YYYY):		Address (number, street, city, province, postal code):	

Please indicate preferred contact number and if there are any times when telephone contact with you about your claim would be most convenient.

May we contact you by email? (Note that some correspondence may still need to be sent by regular mail).

Yes  No If yes, please provide email address: \_\_\_\_\_

**Tell us if you have been on this drug before**

Is the patient currently on, or previously been on this drug?  Yes  No

If Yes, a) indicate start date (DD/MM/YYYY): \_\_\_\_\_

b) coverage provided by: \_\_\_\_\_

(if coverage is not provided by Canada Life please provide pharmacy print-out showing purchase of this drug)

**Tell us if you have coverage with any other benefits plan**

Does the patient have drug coverage under any other group benefits plan?  Yes  No

If Yes, name of other Insurance Company: \_\_\_\_\_

If other plan is with Canada Life, tell us the plan and ID number: \_\_\_\_\_

Name of plan member: \_\_\_\_\_

Relationship to patient: \_\_\_\_\_

**Provide details and attach documentation of acceptance or decline:**

\_\_\_\_\_  
\_\_\_\_\_

**Tell us about any Provincial or other coverage you may have**

Does the patient have coverage under a provincial program or from any other source?  Yes  No

If Yes, name of program or other source: \_\_\_\_\_

Provide details and attach documentation of acceptance or decline: \_\_\_\_\_

Is the patient currently receiving disability benefits for the condition for which this drug has been prescribed?  Yes  No

**Tell us about any Patient Assistance Program you might be enrolled in**

Has the patient enrolled in the patient assistance program for this drug?  Yes  No

If Yes, please provide the following information:

1. Patient assistance program patient ID Number: \_\_\_\_\_

2. Patient assistance program contact person name and phone number:

Contact Name: \_\_\_\_\_ Phone Number: \_\_\_\_\_

## Physician Information Verzenio (abemaciclib)

**Note to Physician:** In order to assess a patient's claim for this drug, we require detailed information on the patient's prescription drug history as requested below.

Attach extra information if necessary. **GENETIC TEST RESULTS ARE NOT REQUIRED**

**Physician's Information (please print)**

Name of prescribing physician: \_\_\_\_\_

Specialty: \_\_\_\_\_

Address (number, street, city, province, postal code): \_\_\_\_\_

Telephone Number (including area code): _____	Fax Number (including area code): _____
---	---

1. Prescribed dosage and regimen:

- 150mg po twice daily
  - 200mg po twice daily
  - Other (please specify): \_\_\_\_\_
- Provide rationale: \_\_\_\_\_

2. Health Canada Indication (include date of initial diagnosis)(MM/YYYY): \_\_\_\_\_

- Breast Cancer, advanced or metastatic
  - In combination with an aromatase inhibitor (Refer "Breast Cancer, advanced or metastatic" section and answer questions 1-3)
  - In combination with fulvestrant (Refer "Breast Cancer, advanced or metastatic" section and answer questions 4-8)
  - Single agent (Refer "Breast Cancer, advanced or metastatic" section and answer questions 9-12)
- Other (approved by Health Canada): \_\_\_\_\_

Complete questions 1 - 6 and Other condition (Health Canada approved)

Is this drug being prescribed in accordance with approved Health Canada indications?\*

- Yes, complete indicated questions and Physician's Information
  - No, prescribed use is not approved by Health Canada: \_\_\_\_\_
- Complete questions 1 -6 and Off-label use

**\*Approved Health Canada Indications and Clinical Use for (Verzenio):**

VERZENIO™ (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer

- in combination with an aromatase inhibitor in postmenopausal women as initial endocrine based therapy.
- in combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone (GnRH) agonist.
- as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens. At least one chemotherapy regimen should have been administered in the metastatic setting, and at least one should have contained a taxane.

**Physician's Information (continued) (please print)**

3. What is the anticipated duration of treatment with this drug? \_\_\_\_\_
4. Where will treatment be administered?  Home  Physician's Office  Private clinic  Hospital in-patient  Hospital out-patient
5. Please provide medical rationale why this drug has been prescribed instead of an alternate drug in the same therapeutic class. **Genetic test results are not required.**
- \_\_\_\_\_
- \_\_\_\_\_

**6. Drug and Treatment History – must be completed for every request.**

Drug(s) and Treatment(s) past and present	Dosing Regimen	Start Date (DD/MM/YYYY)	End Date (DD/MM/YYYY)	Clinical Results/Outcome
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____
				<input type="checkbox"/> Failure <input type="checkbox"/> Intolerance <input type="checkbox"/> Other Clinical details: _____ _____

**Breast Cancer, advanced or metastatic – Genetic test results are not required**

**In combination with an aromatase inhibitor**

1. Is patient post-menopausal?  Yes  No
2. Has patient received systemic therapy for advanced disease?  Yes  No
3. Will Verzenio be used in combination with an aromatase inhibitor?  Yes  No

**In combination with fulvestrant**

4. Patient has experienced disease progression during or within 12 months following (neo)adjuvant endocrine therapy, or while receiving endocrine therapy for advanced disease?  Yes  No
5. Has patient received more than 1 endocrine therapy for advanced disease?  Yes  No
6. Has patient received prior chemotherapy for advanced disease?  Yes  No
7. Patient is (select one):  post-menopausal  pre- or perimenopausal
- If pre- or perimenopausal will patient be treated with a gonadotropin-releasing hormone (GnRH) agonist?  Yes  No
8. Will Verzenio be used in combination with fulvestrant (Faslodex)?  Yes  No

**Single agent**

9. Has patient experienced disease progression following endocrine therapy?  Yes  No
10. Has patient received at least 1 chemotherapy regimen in the metastatic setting?  Yes  No
11. Has the patient received 1 or more taxane containing chemotherapy regimen?  Yes  No
12. Will Verzenio be used as monotherapy?  Yes  No

## Physician Information Verzenio (abemaciclib)

### Other condition (Health Canada approved) – Genetic test results are not required

Please provide any relevant information related to the disease and attach supporting documentation.

---

---

### Off-label use – Genetic test results are not required

**Questions 1 – 6 must be completed.**

Date of initial diagnosis (MM/YYYY): \_\_\_\_\_

Is there clinical evidence supporting the off-label use of this drug?  Yes  No

Provide clinical literature/studies to support the request for off-label use, such as:

- At least two Phase II or two Phase III clinical trials showing consistent results of efficacy; and
- Published recommendations in evidence-based guidelines supporting its use.

Provide medical rationale why this drug has been prescribed off-label instead of an alternative drug with an approved indication for this condition.

---

---

Provide any pertinent medical history or information to support this off-label request.

---

---

If this is a renewal request, provide documentation showing efficacy since previous request.

---

---

**Note for Physician: To be eligible for reimbursement, Canada Life may require your patient to purchase a drug requiring prior authorization from a pharmacy designated by Canada Life. If applicable, a health case manager will contact you with further information.**

**I certify that the information provided is true, correct, and complete.**

Physician's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

License Number: \_\_\_\_\_

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. This form may be subject to audit. The completed form can be returned to Canada Life by mail, fax, or email.

**Note:** As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

**Mail to:** The Canada Life Assurance Company  
Drug Claims Management  
PO Box 6000  
Winnipeg MB R3C 3A5

**Fax to:** The Canada Life Assurance Company  
Fax 1-204-946-7664  
Attention: Drug Claims Management

**Email to:** [cldrug.services@canadalife.com](mailto:cldrug.services@canadalife.com)  
Attention: Drug Claims Management